The partners will develop a test to identify women most likely to benefit from VGX-3100, Inovio's immunotherapy to treat HPV-associated advanced cervical dysplasia.
CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.
In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.
